Answers are grounded in this paper and cite their sources.
Longitudinal observational study explores diagnosis, clinical features, and treatment in pediatric PHA patients, suggesting a need for improved management.
Progressive hemifacial atrophy (PHA) or Parry-Romberg syndrome is a rare, insidiously progressive disorder that typically presents in childhood and is considered part of the morphea spectrum. This longitudinal, ambispective, observational study included 8 pediatric patients (4 female) diagnosed with PHA, with a mean age at symptom onset of 4.5 ± 2 years and at diagnosis of 8.2 ± 2.9 years. All 8 patients presented superficial and deep cutaneous findings (dyspigmentation, dermal and subcutaneous atrophy, and facial asymmetry); 7 had associated extracutaneous abnormalities (maxillofacial, ophthalmological, and neurological), all received systemic immunosuppressive therapy (average of 2.2 ± 1 regimens for a mean duration of 35.2 ± 29.3 months), and 4 had subsequent fat grafting procedures. In conclusion, pediatric patients with PHA suffer an important diagnostic delay, require long-term treatment with multiple immunosuppressive drugs and surgical interventions, as well as multidisciplinary management of frequent associated extracutaneous abnormalities.
No takes yet. Share an insight, caveat, or question.
Zúñiga‐González et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: